Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors

21. juli 2026 oppdatert av: Jinsong Wu, Huashan Hospital

AI-Assisted Presurgical MRI Molecular Subtyping for Pediatric Brain Tumors: A Single-Center Ambispective Clinical Cohort Study

This multicenter observational cohort study aims to develop and validate an artificial intelligence (AI)-assisted diagnostic system for preoperative molecular subtyping of pediatric brain tumors using routine magnetic resonance imaging (MRI). The study will include seven major pediatric brain tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor (AT/RT), intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors.

The study includes a retrospective cohort for model development and internal/external validation, and a prospective cohort for further validation. Retrospective data will be collected from pediatric patients who underwent first surgical treatment between January 1, 2020 and December 31, 2025. Prospective enrollment will begin on July 15, 2026, with an anticipated sample size of 150 participants. The AI system will analyze preoperative MRI sequences, including T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR images, to predict key molecular markers and integrated diagnostic categories. The primary objective is to evaluate the diagnostic performance of the AI system for prespecified molecular prediction tasks using postoperative histopathology and molecular testing as the reference standard. Secondary objectives include assessing agreement with integrated diagnosis, comparing performance against blinded radiologists, and exploring prognostic associations of AI-predicted subgroups.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Detaljert beskrivelse

Pediatric brain tumors are the most common solid tumors in children and represent a highly heterogeneous group of diseases with marked variation in histology, molecular alterations, anatomic location, treatment response, and prognosis. Several molecular features, including H3K27M mutation, BRAF V600E mutation, ZFTA fusion, SMARCB1 loss, CTNNB1 mutation, and TP53 alteration, are clinically important for diagnostic classification, risk stratification, prognosis assessment, and treatment planning. However, most molecular characterization currently depends on postoperative tissue-based testing, and noninvasive preoperative prediction remains limited.

This study is designed to evaluate an AI-assisted MRI-based diagnostic system for pediatric brain tumors in a real-world multicenter observational setting. The study will include seven target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors. The retrospective component will collect multimodal data, including clinical variables, preoperative MRI, pathology reports, molecular testing results, treatment information, and follow-up data, from eligible pediatric patients treated from January 1, 2020 through December 31, 2025. The prospective component will consecutively enroll eligible patients from July 15, 2026 onward for additional validation of model performance.

Preoperative MRI data will be preprocessed using standardized procedures, including bias field correction, skull stripping, isotropic resampling, and intensity normalization. The AI model will be developed to support classification of tumor type and prediction of key molecular subtypes/markers from presurgical MRI. Model performance will be evaluated using postoperative pathology and molecular testing as the reference standard. The primary endpoint is the area under the receiver operating characteristic curve (AUC) for prespecified molecular prediction tasks. Secondary analyses will evaluate agreement between AI output and integrated final diagnosis, comparative performance against blinded radiologists on independent test sets, multiclass tumor classification performance, biomarker-specific sensitivity and specificity, and progression-free survival stratified by AI-predicted subgroup.

This study is observational and is not intended for medical device registration. Biospecimen banking is not a registration objective of this study.

Studietype

Observasjonsmessig

Registrering (Antatt)

1400

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Pediatric patients with suspected primary brain tumors who undergo first surgical treatment at participating centers and whose postoperative pathology confirms one of seven predefined tumor categories.

Beskrivelse

Inclusion Criteria:

  • Age younger than 18 years at the time of index surgery.
  • Evaluated at a participating study center and scheduled for first surgical treatment of a suspected target pediatric brain tumor.
  • Preoperative brain MRI available before surgery, including at minimum T1-weighted, contrast-enhanced T1-weighted, T2-weighted, and FLAIR sequences in DICOM format; MRI preferably performed within 7 days before surgery and before biopsy or tumor-directed therapy.
  • Postoperative histopathology confirming one of the following target tumor categories: glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, or choroid plexus tumors.
  • For the prospective cohort, written informed consent provided by a parent or legal guardian, with child assent obtained when appropriate according to age, understanding, and local ethics requirements.

Exclusion Criteria:

  • Postoperative pathology confirming a non-target tumor type.
  • Recurrent tumor, repeat surgery, or prior tumor-directed surgery before the index surgery.
  • Preoperative MRI of inadequate quality for analysis, including severe motion artifact, severe susceptibility/metal artifact, or incomplete field of view.
  • Prior biopsy, radiotherapy, chemotherapy, or other tumor-directed treatment before the index preoperative MRI that is judged to substantially affect imaging interpretation.
  • Concurrent malignant disease other than the target brain tumor.
  • Inability to comply with follow-up requirements in the prospective cohort, in the investigator's judgment, because of severe comorbidity or other practical limitations.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Retrospective Cohort
Pediatric patients younger than 18 years who underwent first surgical treatment for one of the target brain tumors between January 1, 2020 and December 31, 2025, with available preoperative MRI and postoperative pathological confirmation. Data from this cohort will be used for model development and validation.
Prospective Cohort
Consecutively enrolled pediatric patients younger than 18 years meeting eligibility criteria from July 15, 2026 onward. Data from this cohort will be used for prospective validation of AI diagnostic performance.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Area Under the Receiver Operating Characteristic Curve (AUC) for MRI-Based Prediction of Prespecified Molecular Markers
Tidsramme: Assessed at final model evaluation using all eligible retrospective cases collected from January 1, 2020 through December 31, 2025 and all eligible prospectively enrolled cases with available reference-standard data collected from July 15, 2026 through D
Diagnostic discrimination of the AI-assisted system for binary prediction of prespecified key molecular markers or molecular subtypes from preoperative MRI, using postoperative histopathology and molecular testing as the reference standard. AUC values and 95% confidence intervals will be calculated for each prespecified molecular prediction task.
Assessed at final model evaluation using all eligible retrospective cases collected from January 1, 2020 through December 31, 2025 and all eligible prospectively enrolled cases with available reference-standard data collected from July 15, 2026 through D

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Agreement Between AI-Based Diagnosis and Integrated Final Diagnosis
Tidsramme: Assessed at final diagnostic adjudication for each eligible participant from study start on July 15, 2026 through study completion on December 30, 2029, including retrospective cases with complete reference-standard data.
Agreement between AI-predicted diagnostic output based on preoperative MRI and the integrated final diagnosis established from imaging, postoperative histopathology, and molecular testing. Agreement will be quantified using Cohen's kappa coefficient.
Assessed at final diagnostic adjudication for each eligible participant from study start on July 15, 2026 through study completion on December 30, 2029, including retrospective cases with complete reference-standard data.
Comparative Diagnostic Performance of the AI System Versus Blinded Radiologists
Tidsramme: Assessed at blinded reader evaluation after completion of dataset curation and test set locking, anticipated by December 30, 2029.
Comparison of sensitivity, specificity, accuracy, and AUC between the AI system and radiologists blinded to pathology and molecular results on a predefined independent test dataset.
Assessed at blinded reader evaluation after completion of dataset curation and test set locking, anticipated by December 30, 2029.
Macro-Average AUC for Seven-Class Tumor Classification
Tidsramme: Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Macro-average area under the receiver operating characteristic curve for classification of the seven target pediatric brain tumor categories.
Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Weighted F1 Score for Seven-Class Tumor Classification
Tidsramme: Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Weighted F1 score of the AI system for multiclass classification across glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, intracranial germ cell tumors, craniopharyngioma, and choroid plexus tumors.
Assessed at final model evaluation using eligible cases with complete imaging and reference-standard diagnostic data through December 30, 2029.
Sensitivity and Specificity for Prediction of Key Molecular Biomarkers
Tidsramme: Assessed at final model evaluation using cases with complete biomarker reference-standard results through December 30, 2029.
Sensitivity and specificity of the AI system for prediction of tumor-specific biomarkers, including but not limited to H3K27M mutation, BRAF V600E mutation, ZFTA fusion, SMARCB1 loss, CTNNB1 mutation, and TP53 alteration, depending on tumor type and data availability.
Assessed at final model evaluation using cases with complete biomarker reference-standard results through December 30, 2029.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

15. juli 2026

Primær fullføring (Antatt)

30. desember 2029

Studiet fullført (Antatt)

30. desember 2029

Datoer for studieregistrering

Først innsendt

8. juli 2026

Først innsendt som oppfylte QC-kriteriene

8. juli 2026

Først lagt ut (Faktiske)

14. juli 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .